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Abstract
Objectives: The mechanisms by which low oxygen availability are associated with the development of insulin resistance
remain obscure. We thus investigated the relationship between such gluco-insular derangements in response to sustained
(hypobaric) hypoxemia, and changes in biomarkers of oxidative stress, inflammation and counter-regulatory hormone
responses.
Methods: After baseline testing in London (75 m), 24 subjects ascended from Kathmandu (1,300 m) to Everest Base Camp
(EBC;5,300 m) over 13 days. Of these, 14 ascended higher, with 8 reaching the summit (8,848 m). Assessments were
conducted at baseline, during ascent to EBC, and 1, 6 and 8 week(s) thereafter. Changes in body weight and indices of
gluco-insular control were measured (glucose, insulin, C-Peptide, homeostasis model assessment of insulin resistance
[HOMA-IR]) along with biomarkers of oxidative stress (4-hydroxy-2-nonenal-HNE), inflammation (Interleukin-6 [IL-6]) and
counter-regulatory hormones (glucagon, adrenalin, noradrenalin). In addition, peripheral oxygen saturation (SpO2) and
venous blood lactate concentrations were determined.
Results: SpO2 fell significantly from 98.0% at sea level to 82.0% on arrival at 5,300 m. Whilst glucose levels remained stable,
insulin and C-Peptide concentrations increased by .200% during the last 2 weeks. Increases in fasting insulin, HOMA-IR and
glucagon correlated with increases in markers of oxidative stress (4-HNE) and inflammation (IL-6). Lactate levels
progressively increased during ascent and remained significantly elevated until week 8. Subjects lost on average 7.3 kg in
body weight.
Conclusions: Sustained hypoxemia is associated with insulin resistance, whose magnitude correlates with the degree of
oxidative stress and inflammation. The role of 4-HNE and IL-6 as key players in modifying the association between sustained
hypoxia and insulin resistance merits further investigation.
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Introduction
Ascent to high altitude is associated with a fall in barometric
pressure, and with it a reduction in oxygen availability (‘hypobaric
hypoxia’). Such exposure, whether in the short- or long-term) leads
to diverse endocrine responses (e.g. in insulin signalling, thyroid
function and sympatho-adrenal activity [1–12]).
Hypobaric hypoxia may also affect the gluco-insular axis.
However, data have been inconsistent or contradictory [3–6,12–
14]: beneficial effects of hypoxia on peripheral insulin action and
body weight regulation have, for instance, been suggested [5,6,15]
whereas a deterioration of insulin signalling has been reported in
other studies [3,7]. The source of such conflicting data may relate
to inter-study differences in 1) sample size, 2) intensity of exposure
to hypoxia (rate of ascent and maximum height gained: ascent
profile) 3) duration of exposure to hypoxia, 4) subjects’ phenotypic
characteristics, 5) exposure to other environmental stressors (e.g.
physical exertion and altered energy balance), and 6) testing
conditions (chamber, high-altitude) [16]. Operation Everest II
(simulated ascent of Mount Everest over 40 days in a hypobaric
chamber) tried to obviate the effect of some of these confounders,
with homogenous ascent profile, diet and exercise regime. A key
finding was that some endocrine responses were more marked
during the last week of the intervention when subject were exposed
to the lowest oxygen concentrations [14,17]. Of note, insulin
concentrations at the end of the study were typically 2-fold greater
than those at the start, while glucose levels remained unaltered,
suggesting the development of insulin resistance [14].
Such findings are of possible importance to the pathogenesis of
disease at sea level: there is renewed interest in the role of chronic
hypoxia as a potential causative factor in the pathogenesis of
insulin resistance. Indeed, chronic intermittent hypoxia (CIH) due
to obstructive sleep apnea (OSA) may contribute to the
development and progression of insulin resistance and diabetes
[18–21]. OSA appears to be a predictor of abnormal glucose
metabolism in chronically sleep deprived obese adults [19].
Such effects on insulin resistance may be specifically mediated
through the genesis of associated adipose tissue hypoxia (ATH)
[22], This, in turn, may related to the occurrence of enhanced
adipocyte growth, which may not be accompanied by a parallel,
functional expansion of stromal and vascular tissue to adequately
satisfy the nutritive requirements of the newly formed tissue [23–
25]. A consequent decrease in convective and diffusive oxygen flux
may result in reduced cellular oxygen availability leading to a
progressive impairment of oxidative energetic reactions [26].
Prolonged cell/tissue hypoxia induces adaptive mechanisms
including production of reactive oxygen species (ROS), inflam-
matory adipokines and adipose tissue macrophage infiltration. In
addition, hypoxic exposure may also affect gluco-insular homeo-
stasis by increasing systemic inflammation [27] and modification
of pancreatic b-cell function [28].
Progressive exposure of human volunteers to hypobaric hypoxia
at high altitude provides an opportunity to explore associations
between hypoxia, oxidative stress, inflammation and gluco-insular
deregulation as well as to identify novel mechanistic targets. The
2007 Caudwell Xtreme Everest (CXE) expedition [16] provided
such an opportunity. We evaluated whether sustained hypoxemia
was associated with alterations in glucose and insulin homeostasis.
Specifically, patterns of change in indices of insulin resistance
(homeostasis model assessment of insulin resistance, HOMA-IR)
[29], insulin secretion (C-Peptide) and hepatic insulin extraction
(C-Peptide/Insulin Ratio) [30] were evaluated. In addition, we
investigated the role of oxidative stress (Isoprostanes (8-iso-
prostaglandin F-2a) and 4-hydroxy-2-nonenal (4-HNE), Total
Glutathione, Reduced Glutathione (GSH), Oxidized Glutathione
(GSSG)) and inflammatory biomarkers (Interleukin 6 (IL-6), C
Reactive Protein (CRP), Macrophage Migration Inhibitory Factor
(MIF), Tumour Necrosis Factor Alpha (TNF-Alpha) and counter-
regulatory hormones (Glucagon, Adrenalin, Noradrenalin) as
putative causal factors linking hypobaric hypoxia to changes in
gluco-insular action.
Methods
The study was approved by the University College of London
(UCL) Research Ethics committee, in accordance with the
Declaration of Helsinki. Verbal and written informed consent
was obtained from all subjects. The study took place between
January and June 2007.
Subjects
Twenty-four healthy subjects (18 male; mean age 35.2 y; range
19–59 y) who were investigators on the CXE 2007 research
expedition to Mount Everest participated in this study [16]. All
subjects were sea level natives free of cardiovascular or respiratory
disease and took no medication. Criteria for participation have
been described elsewhere [16].
Study Protocol
The design and conduct of this study is described elsewhere
[16]. Briefly, subjects underwent baseline testing in London
(altitude 75 m) before travelling by plane to Kathmandu, Nepal
(1,300 m). From there they flew to Lukla (2,800 m) on expedition
day 1 and then trekked to Everest Base Camp (EBC; 5,300 m),
arriving on expedition day 13. The ascent profile is detailed in
Table S1 in File S1. Testing was repeated during the ascent in
field laboratories in Kathmandu (1,300 m; day 23 to 0), Namche
(3,500 m; day 4 to 6), Pheriche (4,250 m; day 9 to 10), and at EBC
(5,300 m; day 15 to 17, EBC week 1). The subjects were then
divided into two subgroups: Group 1 (laboratory staff) subse-
quently remained at EBC for the duration of the expedition
(n= 10), whilst Group 2 (climbers; n = 14) subsequently ascended
above 5,300 m, to a maximum of 8,848 m on Mount Everest.
Measurements were repeated in both groups at EBC (5,300 m) at
week 6 and week 8. Ambient temperatures were well controlled
during testing [16].
Plasma Biomarker Analyses
Blood sampling. All blood samples were taken prior to
exercise testing and drawn from the antecubital vein. Plasma was
separated from blood cells by centrifugation of whole blood at
8006g for 15 min and immediately frozen in 1 ml aliquots in
liquid nitrogen. Samples were stored in liquid nitrogen for the
duration of the expedition (including carriage back to Kath-
mandu), transported back to the UK on dry ice, then stored at 2
80uC in a commercial cryostorage facility until analysis. A
summary of the number of samples available for each biomarker
is reported in Table S2 in File S1.
Peripheral oxygen saturation. SpO2 was measured in the
morning of the same day that blood was analyzed, after 10
minutes of rest, using a pulse oximeter (Onyx 9500, Nonin, USA).
Measurements were taken by independent individuals, with the
subject blind to oximeter data (thus preventing feedback to alter
respiratory rate, and hence SpO2).
Oxidative Stress Markers. Isoprostanes (8-iso-prostaglan-
din F-2a) and 4-hydroxy-2-nonenal (4-HNE) were quantified using
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direct competitive enzyme immunoassay (Assay Designs, Ann
Arbor, MI) and ELISA (OxiSelect HNE-His Adduct ELISA kit,
Cell Biolabs, San Diego, CA), respectively. Reduced and oxidized
glutathione were determined spectrofluorimetrically (DetectX,
Arbor Assays, Ann Arbor, MI). For methodological reasons, this
assay overestimates oxidized glutathione; thus reported values
should not be misinterpreted to reflect true circulating concentra-
tions.
Inflammatory Markers. Interleukin-6, TNF-a and MIF
were quantified using xMAP technology (Human-Cytokines-12-
plex-panel, BioRad) on a Luminex/Bio-Plex-200 System with
high-throughput fluidics (BioRad).
Glucose, Insulin and C-Peptide. Plasma glucose levels were
measured with the glucose oxidase method. Insulin and C-Peptide
levels were determined using the Bio-Plex-Pro-Human-Diabetes
12-plex panel (BioRad).
Counter-regulatory hormones. Glucagon was measured
with the Bio-Plex-Pro-Human-Diabetes 12-plex panel (BioRad).
Adrenalin and Noradrenalin were quantified using a direct
competitive enzyme immunoassay (Bi-CAT ELISA, Alpco Diag-
nostics, Salem, NH).
Lactate, Creatinine and Osmolality. Lactate and creati-
nine concentrations were determined colorimetrically by coupled
enzymatic reactions using commercial assay kits (Sigma). Plasma
osmolality was measured using freezing point depression (Model
3320 Micro-Osmometer, Advanced Instruments, Inc).
Assessment of insulin resistance. The degree of insulin
resistance was estimated by the homeostasis model assessment of
insulin resistance (HOMA-IR) and the fasting glucose/insulin ratio
(FGIR). HOMA-IR was computed as follows: fasting insulin (mIU/
ml) 6 fasting glucose (mmol/ml)/22.5 [29]. C-Peptide is a
fragment cleaved from pro-insulin and secreted in amounts
equimolar to those of insulin [31]. The longer half-life and the
minimal hepatic first-pass extraction compared to insulin support
the utilisation of C-Peptide as a measure of b-cell secretion [32].
The fasting C-peptide–to–insulin ratio was calculated as a measure
of hepatic insulin extraction (C-peptide–to–insulin ratios decrease
as hepatic insulin extraction decreases) [30].The C-Peptide/
Insulin ratio can be used as a surrogate measure of hepatic insulin
clearance which is correlated with hepatic insulin effects [33]. The
glucagon-insulin ratio was calculated as an index of the pancreatic
endocrine response [34].
Statistical Analysis
Variables were inspected for normality of distribution using the
Q-Q and the Shapiro-Wilk tests, and appropriate transformations
were utilised (where necessary) to normalise the data before
statistical analysis. However, we also reported untransformed
values so as to provide more interpretable information on the
changes of the various biomarkers; median and inter-quartile
range (25th and 75th percentile) were used as descriptive statistics.
A general linear model for repeated measures was used to analyse
changes in biomarker concentrations during the expedition. The
Bonferroni post-hoc test was used to evaluate significant changes
relative to baseline (London). The method proposed by Bland and
Altman was utilised to calculate within-subject coefficients of
correlation to evaluate significant associations between variables
[35]. Multiple-testing was taken into account and the criterion for
statistical significance was therefore set at a p value ,0.001.
Analyses were conducted using SPSS-19 for Windows and
Sigmaplot-11 for Windows.
Results
Baseline Characteristics and Weight Changes
Twenty-four subjects participated in the expedition; 2 subjects
were excluded because biomarkers data were missing, leaving data
from 22 subjects (17 males) included in the final analysis. Subjects
were stratified according to their main task during the expedition:
Group 1 (EBC laboratory staff; n = 10) and Group 2 (climbers;
n = 12). The two groups were well matched for BMI and
circulating levels of biomarkers involved in glycaemic control,
indices of insulin resistance, inflammation (IL-6, CRP, TNF-a,
MIF), oxidative stress and SpO2. While glucose levels were within
the normal range, levels of fasting insulin, C-Peptide and HOMA-
IR exceeded expected physiological levels (Table 1). Subjects lost
body weight during the expedition (-7.365.0 kg, p,0.001), with
climbers losing more weight than EBC residents (29.0 kg vs 2
4.3 kg respectively, p = 0.03) (Figure S1 in File S1). The average
rate of weight loss during the expedition was 173 g/day.
Evidence of Hypoxemia, and Lactate, Osmolality and
Creatinine Changes
During ascent, median peripheral oxygen saturation (SpO2) fell
from 98.0% at sea level to 82.0% on arrival at 5,300 m (p,0.001)
and improved marginally with time spent at that altitude (87.0%
on EBC day 71; Table S1 in File S1). SpO2 measured at EBC
was not different between climbers and EBC team during the
entire expedition.
Baseline lactate levels were within the normal range
(1.3960.42 mmol/L). They progressively increased during the
ascent, peaked at EBC week 1 (2.1260.89 mmol/L; p,0.001) and
remained elevated at EBC week 6 (1.7860.53 mmol/L; p,0.05)
and week 8 (1.8960.48 mmol/L; p,0.05). Osmolality did not
change during the expedition (Baseline: 292.965.8 mOsm/kg;
EBC week 8: 291.1612.5 mOsm/kg; p.0.05). Creatinine levels
were unmodified until EBC week 6 but showed a significant
increase in both groups at the end of the study (baseline:
0.8260.11 mg/dl; EBC week 8: 1.0360.16 mg/dl, p,0.001).
Hypoxemia and Gluco-Insular Homeostasis
Glucose levels were maintained within the normal range
throughout the expedition and no differences were observed
between the two groups (Figure 1a). Low glucose levels (,
3 mmol/L) were mostly observed during the ascent phase (6
measurements) whereas only one low value was observed at high
altitude (EBC week 6, climbers). A different pattern was observed
for insulin axis responses. Insulin levels increased slightly during
the ascent and returned to baseline values at the end of the first
week at EBC. However, fasting insulin levels increased by 250%
after 6 weeks at EBC (p,0.001) and this was maintained until the
end of the expedition (p,0.001, EBC 8 weeks) (Figure 1b).
Changes of comparable magnitude were observed for C-Peptide
(Figure 1c), HOMA-IR (Figure 1d) and FIGR (reversed
changes, Figure 1e). The C-Peptide/Insulin ratio appeared to
be minimally affected by the prolonged exposure to hypoxia
(Figure 1f).
Counter-Regulatory Hormones
Glucagon levels had risen significantly by week 6 (p,0.001) and
week 8 (p,0.001), albeit to a lesser proportional extent than those
of insulin and C-peptide. No differences in the responses were
found between climbers and EBC residents (Figure 2a). One
week after arrival at EBC, Adrenalin and Noradrenalin concen-
trations changed in opposite directions, and the response to
sustained hypoxia was greater for Adrenalin (Figure 2b) com-
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pared to Noradrenalin (Figure 2c). The glucagon-insulin ratio
decreased significantly during the last two weeks of the expedition
(p,0.001) (Figure 2d).
Biomarkers of Oxidative Stress
We have previously reported some of these data [36]. Levels of
total glutathione and related biomarkers (GSH, GSSG, GSH/
GSSG) were compared to the values taken at the start of the ascent
(Kathmandu, 1,300 m), due to unavailability of baseline measures
for London. responses varied substantially between individuals,
with a non-significant trend for total glutathione and GSH to
increase at high altitude (Figure 3a–d). Marked inter-individual
variation in Isoprostane levels (8-isoPGF) was also identified, with
a complex pattern of response to ascent (Figure 3e). By contrast,
4-HNE showed much smaller inter-individual variability and a
direct association with the duration of hypoxia. Changes in
circulating levels were significantly elevated during the ascent and
had increased almost 3-fold by EBC week 6 and week 8 (p,0.001)
(Figure 3f).
Biomarkers of Inflammation
CRP levels did not change significantly (Figure 4a) whilst
TNF-a levels showed a tendency to decline (Figure 4b). MIF
increased only at EBC week 8 (p,0.001) (Figure 4c) whereas the
profile of IL-6 mirrored changes in insulin levels. Specifically, IL-6
levels showed no changes until after EBC week 1 but had
increased by ,250% by EBC week 6 and week 8 (p,0.001)
(Figure 4d).
Correlation Analysis
The main aim of this analysis was to evaluate the associations
between hypoxemia, oxidative stress and inflammatory biomarkers
with glucose, insulin and indices of insulin resistance. A correlation
matrix has been provided in Table S3 in File S1. In addition, a
mechanistic-model of insulin resistance based on the correlation of
HOMA-IR with biomarkers of inflammation and oxidative stress
has been proposed (Figure 5). The model suggests a non-
significant role of CRP whereas a strong and significant association
with HOMA-IR was observed for IL-6 (r = 0.74, p,0.001). The
Table 1. Baseline characteristics of the CXE 2007 Expedition Team and comparison between team members reaching the summit
and members residing at Everest Base Camp during the 8-week expedition.
All Climbers Everest Base Camp p
N 22 12 10 -
Gender (M/F) 17/5 11/1 6/4 -
Age, years 34.05 (24.02, 40.62) 36.15 (31.35, 40.67) 30.85 (25.37, 42.25) NS
Weight, kg 76.0 (66.8, 83.8) 79.5 (70.0, 89.0) 71.0 (63.8, 80.3) ,0.05
Height, cm 178.8 (171.5, 181.0) 180.0 (176.4, 182.1) 174.0 (165.5, 180.3 ,0.05
BMI, kg/m2 24.40 (22.82, 26.07) 24.90 (22.82, 26.37) 23.65 (22.65, 24.92) NS
Glucose, mM/L 4.50 (3.80, 4.90) 4.34 (3.55, 4.84) 4.64 3.85 4.97 NS
Insulin, mU/mL 29.38 (26.55, 34.26) 30.52 (27.51 37.10) 27.91 24.09 32.48 NS
C-peptide, pg/mL 1590.53 (1353.74, 1819.91) 1726.26 (1483.78 1945.38) 1403.26 1302.69 1617.22 NS
HOMA-IR 5.46 (4.56, 6.38) 5.36 (4.61, 6.87) 5.53 (3.92, 6.34) NS
FIGR 2.65 (2.03, 3.39) 2.23 (1.90, 3.10) 3.20 (2.15, 3.41) NS
C-Peptide/Insulin Ratio 1.28 (1.20, 1.43) 1.33 (1.21, 1.58) 1.24 (1.12, 1.32) NS
Glucagon (pg/mL) 339.06 (307.81, 392.21) 351.89 (314.00, 406.17) 334.69 (294.22, 368.83) NS
Adrenalin (ng/mL) 0.02 (0.008, 0.05) 0.01 (0.003, 0.04) 0.02 (0.01, 0.05) NS
Noradrenalin (ng/mL) 0.13 (0.07, 0.16) 0.14 (0.10, 0.17) 0.09 (0.06, 0.16) NS
8-isoPGF, ng/mL 36.20 (28.64, 47.38) 33.94 (29.34, 40.79) 43.45 (27.64, 47.92) NS
4-HNE, mg/mL 108.22 (91.54, 141.28) 105.72 (91.08, 154.09) 110.72 (97.24, 134.77) NS
GSH, mM¥ 0.53 (0.47, 0.57) 0.53 (0.44, 0.56) 0.53 (0.47, 0.60) NS
GSSG, mM¥ 0.20 (0.07, 0.29) 0.17 (0.03, 0.25) 0.27 (0.14, 0.45) NS
GSH/GSSG¥ 2.07 (1.15, 3.98) 2.29 (1.14, 5.84) 1.87 (1.14, 2.77) NS
Total Glutathione, mM¥ 0.91 (0.68, 1.13) 0.88 (0.52, 1.03) 1.07 (0.89, 1.50) NS
IL-6, pg/mL 11.75 (10.11, 14.90) 11.31 (10.04, 15.52) 12.07 (10.13, 14.15) NS
CRP, ng/mL 626.6 (306.2, 2085.4) 480.8 (305.0, 1614.9) 670.08 (452.0, 3043.1) NS
TNF-a, pg/mL 31.31 (27.53, 38.92) 32.89 (27.65, 38.92) 28.85 (26.14, 36.21) NS
MIF (pg/mL) 6714.3 (5503.8, 7047.8) 6806.9 (5816.2, 7260.7) 6316.3 (5306.1, 7004.8) NS
Lactate (mmol/L) 1.30 (1.22, 1.64) 1.35 (1.11, 1.60) 1.27 (1.12, 1.79) NS
SpO2 (%) 97.0 (98.0, 99.0) 97.0 (98.0, 99.0) 97.0 (98.0, 99.0) NS
Data are presented as median (25th and 75th percentile). N = number of subjects; M = Male; F = Female; BMI = body mass index; HOMA-IR = homeostasis model of
assessment-insulin resistance; 8-isoPGF = 8-iso-Prostaglandin F2alpha; 4-HNE = 4-Hydroxynonenal; GSH = reduced glutathione; GSSG= oxidized glutathione; IL-6 =
interleukin 6; CRP= C-reactive protein; TNF-a= tumour necrosis factor alpha; MIF = macrophage migration inhibitory factor; SpO2 = peripheral oxygen saturation. Data
were transformed before analysis. T test was used to determine differences between the two groups. NS = not statistically significant. ¥Data for these biomarkers were
not available from the samples collected in London; therefore we have used the data derived from the samples collected in Kathmandu as baseline levels.
doi:10.1371/journal.pone.0094915.t001
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correlation of oxidative stress with inflammation revealed an
important relationship between IL-6 with 4-HNE (r = 0.48, p,
0.001). 4-HNE was the only oxidative stress biomarkers strongly
correlated with HOMA-IR (r = 0.42, p,0.001) (Figure 5). The
strongest association with insulin and indices of gluco-insular
regulation were observed for glucagon, IL-6 and 4-HNE. SpO2
was weakly associated with biomarkers of insulin resistance (Table
S3 in File S1).
Discussion
The key finding of the present study is that sustained hypoxia
induced a significant increase in IL-6 and 4-HNE concentrations
which were correlated with insulin concentrations and HOMA-IR
levels.
Gluco-Insular Response
Our results are in accord with those from the (hypobaric
chamber-based) simulated ascent of Everest in Operation Everest
II, whose study duration (40 days) and intensity of exposure to
hypoxia was similar for the 6 healthy male participants to that
which our subjects faced [12]: in both studies, glucose- insulin
response was dependent on the duration and intensity of exposure
to hypoxia, with a paradoxical increase in insulin levels during
weight loss [14]. These data are consistent with an increase in
insulin resistance at altitude, resulting in a compensatory increase
in insulin secretion. Such an increase in insulin levels may also
help compensate for the increase in hepatic glucose output
induced by counter-regulatory hormones (glucagon, adrenalin),
whose levels rose by ,70% and ,300%, respectively during the
last two weeks at altitude.
Results from other studies testing the association between
hypoxia and insulin function are conflicting. Short-term exposure
to hypoxia for two days at high altitude was characterised by
increased glucose and insulin levels which progressively returned
to baseline levels within one week [3]. Simulated short-term
(16 hours) exposure to hypoxia (4,300 m) induced a decline in
insulin sensitivity in both women and men [37]. Endocrine
responses to hypoxia have also been investigated in longer studies.
Plasma glucose and insulin levels increased in fifteen healthy
subjects after seven days at 5,080 m but returned to baseline
values at the end of the 41-day expedition. Decreased glycaemia
and stable insulin levels were observed in nine male elite climbers
during their ascent of Mt. Everest [1].
The Operation Everest II study resembles the Caudwell Xtreme
Everest Expedition for study duration and intensity of exposure to
hypoxia. Weight loss in the 6 healthy men making a simulated
(hypobaric chamber) ascent of Mt. Everest over 40days [12] was
similar to that seen in our study (-7.4 kg). This study reported a
two-fold rise of insulin levels with ascent to 335Torr (25days;
altitude equivalent =,5700 m) and 282Torr (32days, altitude
equivalent =,7000 m) that remained elevated until the end of the
study (40days, 282Torr). Plasma glucose concentrations were
unchanged throughout the study [12]. Operation Everest II did
Figure 1. Gluco-insulin axis regulation in members of the research team reaching the summit (N) or remaining at base camp (#)
during the expedition. Homeostatic model of assessment was calculated as a proxy indicator of systemic insulin resistance (HOMA-IR). C-Peptide/
Insulin Ratio was calculated as a measure of hepatic insulin extraction. Median data are presented for the two groups (lines) and all subjects (bars).
Error bars are 25th and 75th percentiles. Significant differences were flagged in each graph: ***p,0.001. No significant differences were observed
between climbers and base camp at either time point.
doi:10.1371/journal.pone.0094915.g001
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not, however, report significant changes in either glucagon or
adrenalin concentrations [12]. Larsen et al measured glucagon
and adrenalin levels in healthy subjects after seven days at high
altitude and found no change in the blood concentrations of either
hormone [3]. In our study, Noradrenalin concentrations peaked as
soon as subjects had to face the first substantial environmental
stressor represented by the ascent to Namche Bazaar at the start of
the trekking expedition [16]. Subsequently, Noradrenalin levels
progressively declined, returning to baseline levels during the last
two weeks of the expedition. A similar pattern for Noradrenalin
concentrations was observed in the Operation Everest II study
[14]. The physiological meaning of the reciprocal changes in
adrenalin and Noradrenalin concentrations at the end of the study
is not clear. Perhaps the elevated metabolic stress occurring during
the last part of the expedition may have posed a greater demand
on systemic functions (metabolic, respiratory) regulated by
adrenalin and, therefore, a reduction of the adrenalin/Noradren-
alin ratio may have enhanced these responses.
The role of hepatic insulin resistance and neo-glucogenesis had
been previously investigated in healthy men exposed to 7-day high
altitude hypoxia (4,559 m) utilising hyperglycaemic euglycaemic
clamps to determine peripheral and hepatic insulin resistance [3].
Insulin action decreased after two days of hypobaric hypoxia but
improved with more prolonged exposure. No effects of hypoxia
were observed on hepatic gluconeogenesis [3]. Glucose and insulin
levels were unchanged during the ascent and the first week at
EBC, suggesting that a longer exposure to hypoxia is needed to
induce changes in insulin signalling.
The effects of prolonged hypoxia exposure on gluco-insular
regulation may be contextualised within a pathogenetic allostatic
metabolic model [38]. Chronic hypoxia represents the allostatic
metabolic load, which initiates a series of adaptive responses
leading to maintenance of physiological function (allostasis). Over
time, the allostatic hypoxic load can accumulate and activate
neural, endocrine, and immune stress responses which in turn
modify glucose and insulin regulation. This concept has been
previously proposed to explain the pathogenesis of hyperglycemia
and insulin resistance [39].
Figure 2. Changes in concentration of counter-regulatory hormones (glucagon, adrenalin, Noradrenalin) and glucagon-insulin
ratio in members of the research team reaching the summit (N) or remaining at base camp (#) during the expedition. Median data
are presented for the two groups (lines) and all subjects (bars). Error bars are 25th and 75th percentiles. Significant differences were flagged in each
graph: ***p,0.001 No significant differences were observed between climbers and EBC lab team members at either time point.
doi:10.1371/journal.pone.0094915.g002
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Changes in 4-HNE and IL-6
The uniqueness of our results is in the identification of a
consistent association between 4-HNE, IL-6 and insulin resistance
(i.e., HOMA-IR), which suggests the existence of a mechanistic
link between these molecules and the development of insulin
resistance during exposure to hypoxia. The two oxi-inflammatory
biomarkers (4-HNE and IL-6) may represent the stress mediators
of chronic exposure to hypoxia. In addition, the associations
appeared to be minimally affected by changes in energy balance as
the oxidative-inflammatory and glucose-insular responses to
hypoxia were similar in both groups, despite the significant
differences in weight changes and physical activity between groups
during the last two weeks of the expedition. These changes
coincided temporally with the increases in insulin concentrations
and HOMA-IR. IL-6 also showed a strong correlation with
glucagon, which suggests that the mechanistic link between the
prolonged exposure to hypoxia and pancreatic endocrine function
may be modified by IL-6.
This study is the first to report the association between sustained
hypoxia, IL-6 and gluco-insular hormones. Hartmann et al
reported increased IL-6 levels in healthy volunteers who spent 3
nights at an elevation above 3,400 m [40]. However, this acute
response was not observed in our study. IL-6 is secreted by
enlarged, activated adipocytes which may result in a systemic
elevation of IL-6 plasma levels leading to insulin resistance [41]. In
muscular tissue, IL-6 may be secreted during physical activity to
act as an energy sensor by activating AMP-kinase and enhancing
glucose disposal. The evidence suggests an association between
chronic elevations of IL-6 and hepatic insulin resistance. IL-6 also
appears to impede maturation of pre-adipocytes and deregulate
the insulin pathway [42]. Therefore, the association of IL-6 with
insulin function is still controversial; our results suggest that, under
chronic hypoxic conditions, IL-6 may be influencing the
physiology of pancreatic endocrine hormones. However, the
causality of the associations and the physiological mechanisms
underpinning these associations remain to be established. Pedersen
et al have summarised the role of IL-6 as a metabolic modulator of
muscular function during exercise [43]. IL-6 concentrations scaled
with exercise duration and intensity but concentrations returned to
basal levels shortly after cessation of exercise [43]. The investiga-
tors concluded that IL-6 plays a physiological role during muscle
contraction as it seems to have anti-inflammatory effects and a role
in fat oxidation, and improved insulin-stimulated glucose uptake
[43]. The metabolic role of IL-6 cannot be ignored in the
interpretation of our results. However, the effects of muscle
contraction on circulating IL-6 concentrations are likely to have
been limited because 1) samples were collected in the morning
after subjects had rested overnight, and 2) plasma IL-6 levels of
base camp residents and climbers were overlapping in spite of very
different physical activity levels during the last part of the
expedition.
Hypoxia is associated with mitochondrial dysfunction and
production of ROS [44]. This is also caused by a reduced capacity
Figure 3. Changes in biomarkers of oxidative stress in members of the research team reaching the summit (N) or remaining at base
camp (#) during the expedition. Median data are presented for the two groups (lines) and all subjects (bars). Error bars are 25th and 75th
percentiles. Data for Total Glutathione, GSH, GSSG and GSH/GSSG were not available from the samples collected in London. Therefore we have used
the data derived from the samples collected in Kathmandu as baseline levels. Significant differences were flagged in each graph: ***p,0.001 No
significant differences were observed between climbers and EBC lab team members at either time point.
doi:10.1371/journal.pone.0094915.g003
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of antioxidant systems leading to increased oxidized glutathione
concentrations and a decline in mitochondrial SOD activity/
content [45]. Increased ROS are associated with oxidative damage
to lipids, proteins, and DNA [46]. Oxidative stress levels seem to
be linearly related to altitude, degree of hypoxia and duration of
exposure. The Operation Everest III study suggested a direct
association as lipid peroxidation increased by 23% at 6,000 m and
79% at 8,848 m [47]. Vij et al studied acclimatization to high-
altitude hypoxia over a period of 13 months, and it appeared that
a period of 3 months was sufficient to increase lipid peroxidation
and decrease enzymatic and non-enzymatic antioxidant defences
[48]. In our study, hypoxia induced progressive changes in
biomarkers of oxidative stress. In particular, 4-HNE levels
increased significantly during the last phase of the expedition
and, interestingly, the inter-subject variability of these responses
was relatively low (CV%: ,45%) compared to isoprostanes
(CV%: ,110%) and reduced glutathione (CV%: ,300%). ROS
production could have a signalling role by communicating the
declined oxidative efficiency of the cells and thereby facilitate
glucose uptake through insulin-independent GLUT-1 [49,50].
The reduction of insulin sensitivity and activation of anaerobic
oxidative pathways could therefore represent an energy-buffer
mechanism to reroute glucose and oxygen towards vital organs
such as brain and heart. Increased insulin secretion during
hypoxia may therefore be a reflection of the increased reliance of
cellular metabolism on glycolysis [26].
Limitations
Subjects were exposed to other extreme environmental condi-
tions (low temperature, physical exertion) in addition to hypoxia
which may confound the associations with metabolic outcomes.
However, although climbers experienced much harsher conditions
Figure 4. Changes in biomarkers of inflammation in members of the research team reaching the summit (N) or remaining at base
camp (#) during the expedition. Median data are presented for the two groups (lines) and all subjects (bars). Error bars are 25th and 75th
percentiles. Significant differences were flagged in each graph: ***p,0.001. No significant differences were observed between climbers and EBC lab
team members at either time point.
doi:10.1371/journal.pone.0094915.g004
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than EBC residents, they did not show higher levels of oxidative
stress, inflammation or insulin levels. This suggests that metabolic
derangements were essentially driven by the prolonged exposure
to hypoxia. We were unable to determine the exact time of onset
of the metabolic derangements as no measurements were taken
between week 1 and week 6 at EBC. Cortisol levels were not
measured during the expedition and any possible association with
changes in insulin and glucagon concentrations cannot therefore
be assessed. Finally, subjects were initially of normal weight and
thence in negative energy balance, which may limit the
transferability of the results to obese subjects in positive energy
balance as a mechanistic model of insulin resistance. However, in
consideration of the established insulin sensitising effects of weight
loss we argue that this study supports the role of systemic hypoxia
in the impairment of gluco-insular action as well as defines a
potential pathogenetic trajectory that may link tissue hypoxia to
insulin resistance in obese subjects.
Conclusions
Healthy humans exposed to sustained hypobaric hypoxia at
high-altitude appear to become insulin-resistant while they are in
negative energy balance. Normo-glycemia was maintained by a
compensatory increase in b-cell secretion and reduced hepatic
extraction leading to sustained hyperinsulinemia during the last
two weeks of the expedition. Previous cellular and animal models
of hypoxia-induced insulin resistance have identified two core
causal mechanisms: over-production of ROS and inflammation
[22]. Our results are aligned with this mechanistic paradigm and
provide evidence to support a causal relationship between hypoxia
and insulin resistance in humans. The role of 4-HNE and IL-6 as
mediators of these effects should be corroborated in future studies.
Ideally, these studies should be conducted in simulated-hypoxic
environments where other factors can be constrained to control for
the confounding effects of weight loss while utilising dedicated
experimental protocols for the assessment of peripheral and
hepatic insulin resistance.
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